<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1133">
  <stage>Registered</stage>
  <submitdate>17/04/2006</submitdate>
  <approvaldate>17/04/2006</approvaldate>
  <nctid>NCT00315757</nctid>
  <trial_identification>
    <studytitle>Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma</studytitle>
    <scientifictitle>A Phase 2, Multi-Center, Open-Label, Randomized Study of Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HGS1012-C1055</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Mapatumumab
Other interventions - Mapatumumab
Treatment: drugs - Bortezomib

Active Comparator: A - Bortezomib

Experimental: B-10 - Bortezomib and Mapatumumab 10 mg/kg

Experimental: B-20 - Bortezomib and Mapatumumab 20 mg/kg


Other interventions: Mapatumumab
10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.

Other interventions: Mapatumumab
20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.

Treatment: drugs: Bortezomib
1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate disease response to mapatumumab in combination with bortezomib and bortezomib alone</outcome>
      <timepoint>17 cycles (up to a year)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the safety, including the frequency and severity of adverse events and laboratory abnormalities, of mapatumumab in combination with bortezomib and bortezomib alone throughout the study period</outcome>
      <timepoint>17 cycles (up to a year)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosed with multiple myeloma that is refractory or has relapsed after treatment

          -  Measurable serum and/or urine M-protein

          -  Failed 1 or 2 prior therapies for multiple myeloma

          -  18 years of age or older</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Received more than 2 prior therapies for multiple myeloma.

          -  Previous cancer therapies (chemotherapy, biologic therapy, radiation therapy or
             immunosuppressants) within the last 3 weeks

          -  Received monoclonal antibodies within the last 3 weeks (chimeric or murine) or 8 weeks
             (human or humanized)

          -  Received investigational (not yet approved by a regulatory authority) agent to treat
             multiple myeloma within the last 4 weeks

          -  Subjects who received a stem cell transplant using cells from themselves in the past
             16 weeks

          -  Subjects who received a stem cell transplant using cells from another individual

          -  Previously treated with bortezomib or mapatumumab

          -  Known HIV, hepatitis-B, hepatitis-C, or hepatitis A infection

          -  Infection requiring antibiotics or hospitalization within the last 2 weeks

          -  Major surgery within the last 4 weeks

          -  Diagnosis with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,
             monoclonal gammopathy, and skin changes)

          -  History of other cancers within the past 5 years

          -  Pregnant or breast-feeding women</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>105</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Department of Haematology, Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Institute of Medical &amp; Veterinary Science - Adelaide</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Clinical Haematology &amp; BMT, Alfred Hospital - Melbourne</hospital>
    <postcode>2065 - St Leonards</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3181 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Human Genome Sciences Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy (disease response) and safety of
      mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or
      refractory multiple myeloma (MM).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00315757</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>